Edwards Lifesciences Corp EW
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Edwards Lifesciences Corp (EW) Business Model and Operations Summary
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Key Insights
Edwards Lifesciences Corp (EW) Core Market Data and Business Metrics
Latest Closing Price
$71.87Market Cap
$42.10 BillionPrice-Earnings Ratio
10.37Total Outstanding Shares
585.76 Million SharesTotal Employees
15,800Dividend
No dividendIPO Date
April 3, 2000SIC Description
Orthopedic, Prosthetic & Surgical Appliances & SuppliesPrimary Exchange
New York Stock ExchangeHeadquarters
One Edwards Way, Irvine, CA, 92614
Historical Stock Splits
If you bought 1 share of EW before May 28, 2010, you'd have 12 shares today.
| Execution Date | Split Amount |
|---|---|
| June 1, 2020 | 3-for-1 |
| December 14, 2015 | 2-for-1 |
| May 28, 2010 | 2-for-1 |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $-1.42 Billion |
| Net Cash Flow From Operating Activities | $806.40 Million |
| Net Cash Flow | $2.27 Billion |
| Net Cash Flow From Investing Activities | $2.90 Billion |
| Net Cash Flow From Operating Activities, Continuing | $806.40 Million |
| Net Cash Flow From Financing Activities, Continuing | $-1.42 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $1.75 Billion |
| Diluted Average Shares | $1.20 Billion |
| Revenues | $6.60 Billion |
| Selling, General, and Administrative Expenses | $1.96 Billion |
| Income/Loss From Continuing Operations After Tax | $1.56 Billion |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $4.16 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-3.80 Million |
| Other Comprehensive Income/Loss | $-2.40 Million |
| Comprehensive Income/Loss | $4.15 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Current Assets | $6.73 Billion |
| Other Current Liabilities | $1.46 Billion |
| Noncurrent Assets | $6.24 Billion |
| Wages | $312.10 Million |
| Current Liabilities | $1.94 Billion |
| Intangible Assets | $956.10 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||